WO2004003159A2 - Nouvelle cible therapeutique pour le traitement de maladies vasculaires, de dyslipidemies et de troubles associes - Google Patents

Nouvelle cible therapeutique pour le traitement de maladies vasculaires, de dyslipidemies et de troubles associes Download PDF

Info

Publication number
WO2004003159A2
WO2004003159A2 PCT/US2003/020410 US0320410W WO2004003159A2 WO 2004003159 A2 WO2004003159 A2 WO 2004003159A2 US 0320410 W US0320410 W US 0320410W WO 2004003159 A2 WO2004003159 A2 WO 2004003159A2
Authority
WO
WIPO (PCT)
Prior art keywords
activity
gene95
polypeptide
hdl
polynucleotide
Prior art date
Application number
PCT/US2003/020410
Other languages
English (en)
Other versions
WO2004003159A3 (fr
Inventor
Alison J. Brownlie
Sherrie Rae Tafuri
Ryan R. Brinkman
Daniel Chagnovich
Aurobindo Chatterjee
Gary C. Donaldson
Marie-Pierre Dube
Yigal P. Goldberg
Leonard F. Jerva
Ronald G. Lafrenier
Erwin Ludwig
Mark E. Samuels
Chenyan Wu
Michael R. Hayden
Original Assignee
Xenon Genetics, Inc.
Warner-Lambert Company, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Genetics, Inc., Warner-Lambert Company, Llc filed Critical Xenon Genetics, Inc.
Priority to JP2004518026A priority Critical patent/JP2006504407A/ja
Priority to EP03762177A priority patent/EP1551856A2/fr
Priority to AU2003247810A priority patent/AU2003247810A1/en
Publication of WO2004003159A2 publication Critical patent/WO2004003159A2/fr
Publication of WO2004003159A3 publication Critical patent/WO2004003159A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to the discovery of gene95, a novel therapeutic target for disease diagnosis and treatment, especially diagnosis and treatment of cardiovascular diseases, such as dyslipidemia and low HDL diseases, including hypoalphalipoproteinemia, as well as therapeutic agents and methods of screening and identifying therapeutic agents useful in preventing, treating or otherwise ameliorating such disorders.
  • cardiovascular diseases such as dyslipidemia and low HDL diseases, including hypoalphalipoproteinemia
  • HDL-C plasma high density lipoprotein cholesterol
  • CVD cardiovascular disease
  • CAD coronary artery disease
  • HDL-C levels are a strongly graded and independent cardiovascular risk factor. Protective effects of an elevated HDL-C persist until 80 years of age. A low HDL-C is associated with an increased CAD risk even with normal ( ⁇ 5.2 mmol/l) total plasma cholesterol levels. Even in the face of other dyslipidemias or secondary factors, HDL-C levels are important predictors of CAD. Low HDL cholesterol (in severe cases called hypoalphalipoproteinemia), is also implicated in cerebrovascular disease, coronary restenosis, and peripheral vascular disease.
  • CVD cardiovascular disease
  • CAD coronary artery disease
  • the present invention relates to the discovery of a new target for therapeutic intervention in the treatment of vascular diseases and dyslipidemias and use of said target to screen for and identify therapeutic agents useful in alleviating low HDL levels and the symptoms of attendant disorders.
  • the present invention provides the complete gene95 cDNA nucleotide sequence (SEQ ID NO: 3) and gene95 amino acid sequence (SEQ ID NO: 4) from humans.
  • the invention further identifies the role and function of gene95 as a key regulator of HDL cholesterol levels by identification of mutant forms of the gene which are associated with inherited low HDL disorders in humans.
  • the present invention provides the purified nucleic acid sequence of gene ⁇ and fragments thereof, including purified and semi- purified forms thereof, as well as recombinant cell lines, viruses or cell extracts containing gene95 nucleotide constructs.
  • the present invention provides the purified gene95 protein and fragments thereof, including purified and semi-purified forms thereof, as well as cells or cell extracts containing gene95 biological activity, and anti-gene95 antibodies, including methods of making such polypeptides.
  • the present invention provides a method for determining whether a candidate compound modulates HDL levels and/or treating a vascular disease or dyslipidemia.
  • the method comprises (a) determining a biological activity of the gene95 gene or protein; (b) contacting a source of this biological activity with a candidate compound under conditions promoting this biological activity; and (c) determining a change in the biological activity of said gene or protein as a result of said contacting, wherein the change in biological activity identifies the candidate compound, or its an analog of the candidate compound, as a compound that modulates said biological activity and is useful in regulating HDL levels and/or treating a vascular disease, dyslipidemia or a related disorder.
  • Other types of assays for Gene95 activity are also specifically contemplated by the present invention.
  • the invention provides a method for computationally identifying a compound for modulating HDL levels and/or treating a vascular disease or dyslipidemia.
  • the method involves (a) determining the active site of the gene95 protein selected (for example, through X-Ray crystallography or other techniques); and (b) through computational modeling, identifying a compound which interacts with the active site, thereby identifying a compound, or an analog thereof, as a compound which is useful for modulating HDL levels and/or treating a vascular disease, dyslipidemia or a related disorder.
  • the invention provides a method for modulating HDL levels and/or treating a vascular disease, dyslipidemia or a related disorder, comprising administering to a person in need thereof, a compound which modulates the activity of gene 95 gene or protein.
  • the invention provides tools for diagnosis of vascular disease and dyslipidemias and/or pharmacogenomics of therapeutic agents for treating vascular disease and dyslipidemias, comprising identification of mutations in the gene95 gene or protein, for example the mutations identified in SEQ ID Nos. 6 - 9 or in Table 1.
  • Figure 1 shows the pedigree of family BC-11 M.
  • Figure 2 shows the pedigree of family NL-003.
  • Figure 3 shows the pedigree of family NL-120.
  • Figure 4 illustrates the expected 10 exon construct of gene95 cDNA. Incomplete constructs assembled from known fragments of gene95 are also illustrated, including other possible transcripts employing E6a or E9a.
  • Figures 5A-5G provide the sequence of exons and introns and the amino acid translation of gene95.
  • Lower case letters intron regions not forming part of mature mRNA or cDNA.
  • "! intron regions available from public database; not included herein.
  • Capital Letters Nucleotide base or Amino Acid (as indicated by context; with standard designations used).
  • "*" a stop codon.
  • +1 , +2, +3 Frameshift for translation of nucleic acid. Short open reading frames before and after the correct amino acid sequence are indicated for completeness, but are not expected to form part of the gene95 protein.
  • exon E1 is part of SEQ ID NO: 18
  • exon E2 is part of SEQ ID NO: 19
  • exon E3 is part of SEQ ID NO: 20
  • exon E4 is part of SEQ ID NO: 21
  • exon E5 is part of SEQ ID NO: 22
  • exon E6 is part of SEQ ID NO: 23
  • exon E7 is part of SEQ ID NO: 24
  • exon E8 is part of SEQ ID NO:
  • exon E9 is part of SEQ ID NO: 26
  • exon E10 is part of SEQ ID NO: 27
  • exon E6a is part of SEQ ID NO: 28
  • exon E9a is part of SEQ ID NO: 29.
  • ctttga SEQ ID NO: 30 shows the start of a new intronic sequence.
  • Figure 6 illustrates the alignment of human (SEQ ID NO: 4) and mouse (SEQ ID NO: 5) amino acid sequences of gene95.
  • Figure 7 shows the alignments of the amino acid sequence of mutation 1 (SEQ ID NO: 7) and mutation 2 (SEQ ID NO: 16) with the wild-type amino acid sequence (SEQ ID NO: 4) of human gene95.
  • Figure 8 illustrates the predicted exon assembly of gene95, with locations of mutations and polymorphisms identified according to the invention.
  • Figure 9 shows a Northern blot with a Gene 95 probe illustrating the results of Example 3.
  • the term “correspond” in the sense of "a gene corresponding to gene95” means that the gene has the indicated nucleotide sequence or that it encodes substantially the same RNA as would be encoded by the indicated sequence, the term “substantially” meaning at least about 50% identical over a sequence encoding a protein with gene95 biological activity; more preferably at least about 60%, 70%, 80%, 90% or higher, and as defined elsewhere herein, including splice variants thereof.
  • “Corresponding to gene95” also includes homologs or orthologs of gene95 from another organism, and sequence variants thereof having at least about 50% identity, at either the nucleotide or amino acid level, and more preferably at least about 60%, 70%, 80%, 90% or higher homology.
  • Preferably such gene is from a eukaryote, more preferably a mammal, more preferably a rodent or human.
  • the human genes and proteins listed in this specification are representative of a wide variety of homologs, orthologs and analogs that may be obtained from other species. These homologs, orthologs and/or analogs, and reasonable variants thereof, can be used in the compositions and methods of this invention.
  • a screening assay which uses the mouse homolog of a listed human gene may also be used in a screening assay to identify potential therapeutic agents for treating humans.
  • the present invention relates to the use of these isoforms, homologs from other species, and analogous sequences which, when translated, retain the biological activity of the isoform, as determined on a region by region basis.
  • Such analogous sequences share preferably greater than 50% identity with SEQ ID NO: 3 or SEQ ID NO: 4, more preferably 60%, 70%, 80% and most preferably at least about 90% identity with the isoforms set out herein. All such sequences may still be useful in practicing the methods of the invention provided that they retain sufficient therapeutic target biological activity so as to determine the effects of test compounds in regulating such activity.
  • Such understanding is available to those skilled in the art based on the teachings disclosed herein.
  • percent identity when referring to a sequence, means that a sequence is compared to a claimed or described sequence after alignment of the sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the "Reference Sequence”).
  • the Percent Identity is then determined according to the following formula:
  • C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence wherein (i) each base or amino acid in the Reference Sequence that does not have a corresponding aligned base or amino acid in the Compared Sequence and (ii) each gap in the Reference Sequence and (iii) each aligned base or amino acid in the Reference Sequence that is different from an aligned base or amino acid in the Compared Sequence, constitutes a difference; and R is the number of bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid.
  • the Compared Sequence has the specified minimum percent identity to the Reference Sequence even though alignments may exist in which the hereinabove calculated Percent Identity is less than the specified Percent Identity.
  • portion when used in relation to polypeptides, refer to a continuous sequence of nucleotide residues, sequence forms a subset of a larger sequence. Such terms include the products produced by treatment of said polynucleotides with any of the common endonucleases, or any stretch of polynucleotides that could be synthetically synthesized. These may include exonic and intronic sequences of the corresponding genes.
  • Therapeutic target biological activity (or just “biological activity”) as used herein is a very broad term that relates to all the directly or indirectly measurable and identifiable biological activities of the therapeutic target gene and protein, including but not limited to those examples set out in (a) - (d) below:
  • therapeutic target biological activity includes, but is not limited to, all those biological processes, interactions, or binding of ligands, proteins, membrane components or other compounds (such as small organic compounds), binding behavior, binding- activity relationships, pKa, pD, enzyme kinetics, stability, and functional assessments of the protein.
  • therapeutic target biological activity includes the rate, scale or scope of transcription of DNA to generate therapeutic target mRNA or its alternate transcripts; the effect of regulatory proteins on such transcription, the effect of modulators of such regulatory proteins on such transcription; plus the stability and behavior of mRNA transcripts, post-transcription processing, mRNA amounts and turnover, and all measurements of translation of the mRNA into polypeptide sequences.
  • therapeutic target biological activity in organisms includes but is not limited to biological activities which are identified by their absence or deficiency in disease processes or disorders caused by aberrant therapeutic target biological activity in those organisms.
  • therapeutic target biological activity can be determined by all these and other means for analyzing biological properties of proteins and genes that are known in the art.
  • a gene and protein associated with maintenance of HDL levels in humans has been determined by identification of mutant forms of the gene in families having low HDL levels using the positional cloning strategy set out in Example 1.
  • the pedigree of family BC-11M is shown in Figure 1.
  • the phenotype in the family used to define the linkage segregates a low HDL (hypoalphalipoproteinemia) trait in an autosomal dominant fashion with high penetrance.
  • Other lipid parameters are normal in this family (including triglyceride (TG) and low density lipoprotein (LDL)) and there is an absence of other confounders (such as obesity and diabetes).
  • cardiovascular disease and coronary artery disease in particular in this family as multiple members have had cardiac events (myocardial infarct (Ml), stroke and angina) and have been treated for symptoms of this disease (such as with coronary artery bypass graft (CABG)).
  • cardiac events myocardial infarct (Ml), stroke and angina
  • CABG coronary artery bypass graft
  • Behcet syndrome related to lupus and auto-immune disorders
  • another member has celiac disease (gluten intolerance) and others have thyroid problems.
  • the pedigree of family NL-003 is shown in Figure 2.
  • the proband (ll:35) has an HDL level below the fifth percentile (age and sex corrected). There are a few cases of overweight/obesity (BMI>25>30) but this condition does not fully co-segregate with the HDL condition and so may not be related.
  • the genes identified according to the invention are located on chromosome 9, at or near the 9q22 band. Markers for this locus have been identified and are as follows: 9q22ca7 (SEQ ID NO: 1) and 9q22ca17 (SEQ ID NO: 2). Other markers are available in the public domain.
  • Gene95 is alternately known and described herein as P1G95, gene95, G95 or as HDL Regulatory Protein. Aspects of Gene95 are described at a variety of different sources in public databases.
  • Goldenpath Gene ID ENSG00000136925, including transcript ID: ENST00000259452. (GoldenPath assembly of the Human Genome Project Working Draft and found at www.genome.ucsc.edu or at the Ensembl website www.ensembl.org, version effective August 2001).
  • the full length cDNA sequence for gene95 (P1G95) is set out in SEQ ID NO: 3 comprising a 4333 bp transcript including 5'UTR and 3' tail.
  • the exon/intron structure of gene95 is set out in Figure 4.
  • the gene comprises 10 exons with possible alternate transcripts for exon 6 ("exon 6 alt” or E6a) and exon 9 ("exon 9 alt” or E9a).
  • Figure 4 illustrates the expected 10 exon construct and other possible transcripts employing E6a or E9a.
  • the gene95 protein comprises a 516 amino acid protein (SEQ ID NO: 4). Use of an alternate methionine start site may generate a sequence of 489 amino acids. Analysis of the protein sequence of gene95 suggests it has the characteristics of a soluble protein which is involved in maintaining serum lipid homeostasis in humans.
  • the protein is believed to contain one or more of the following features: N-glycosylation site (PS00001); Glycosaminoglycan attachment site (PS00002); 4 cAMP- and cGMP-dependent protein kinase phosphorylation sites (PS00004); 12 Protein kinase C phosphorylation sites (PS00005); 8 Casein kinase II phosphorylation sites (PS00006); 8 N- myristoylation sites (PS00008); Zinc finger C2H2 type domain (PS50157); Cysteine-rich region (PS50311).
  • residues 1 -400 represent the 5'-UTR (untranslated region) while the 3'UTR comprises residues 1952-end.
  • residues 1 -400 represent the 5'-UTR (untranslated region) while the 3'UTR comprises residues 1952-end.
  • residues 1 -400 represent the 5'-UTR (untranslated region) while the 3'UTR comprises residues 1952-end.
  • residues 1 -400 represent the 5'-UTR (untranslated region) while the 3'UTR comprises residues 1952-end.
  • residues 1 -400 represent the 5'-UTR (untranslated region) while the 3'UTR comprises residues 1952-end.
  • residues 1 -400 represent the 5'-UTR (untranslated region) while the 3'UTR comprises residues 1952-end.
  • residues 1 -400 represent the 5'-UTR (untranslated region) while the 3'UTR comprises residues 1952-end.
  • residues 1 -400 represent the 5'-UTR (untran
  • Rhodanese-like domain most closely related to group of hypothetical, uncharacterized bacterial proteins.
  • An examplary rhodanese-like domain is found at amino acids 304 - 406. There is no similarity of this gene to any other human gene, other than hypothetical or "rhodanese-like” or "sulfurtransferase-related" proteins.
  • Rhodanese domains are found in a thiosulfate sulfurtransferase (e.g. Rhodanese; IPR001307).
  • a public database search identified 21 hits in human genome with Rhodanese domains, 1 being a platelet adhesion molecule, the others being phosphatases.
  • domain signatures such as a DnaJ central domain (e.g. [CXXCXGXG]4; amino acids 422-480), XS Zinc finger domain (e.g. amino acids 458-465) and integrase site (e.g. amino acids 452- 465) are also suggested.
  • DnaJ central domain e.g. [CXXCXGXG]4; amino acids 422-480
  • XS Zinc finger domain e.g. amino acids 458-46
  • integrase site e.g. amino acids 452- 465
  • Figure 5 sets out the nucleotide and amino acid sequences of individual exons, and some sequence from the promoter (genomic) and intron regions (especially splice site junctions).
  • the Gene95 sequence spans about 34kb of genomic DNA.
  • Introns which are not fully set out may be obtained from the public human genome sequence database Goldenpath. Lower case letters indicate intron and promoter regions, while upper case letters indicate nucleotides in the cDNA or mRNA or amino acids, as dictated by the context.
  • Exon 1 and Exon 2 have one or more asterisks ("*"). These are putative stop codons. The true initiator methionine is believed to be the first methionine in Exon 2 following the asterisk. Asterisks are also found in exon 10.
  • the first asterisk is the expected termination site, generating a polypeptide of 516 amino acids.
  • the remaining amino acid translations are illustrated for the sake of completeness and are not believed to lead to a functioning protein.
  • Exon 6a and Exon 9a contain termination codons. If these alternate exons are used, they are believed to result in the truncated proteins, as indicated.
  • Gene95 are the shared 29 to 34 % identity of Rhodanese-related sulfurtransferases (Salmonella typhimurium and Brucella melitensis) and dihydrofolate reductase (Schizosaccharomyces pombe).
  • Hypothetical bacterial proteins of highest homology include: Q9RVC9_DEIRA/119-216; Q55613_SYNY3/113-210; Q9Z7H1_CHLPN; 084632_CHLPN/113-212; 084632_CHLTR/113-212; 034131J-ACLA/116-213; 031457_BACSU/116-213 (YBFQ protein).
  • mouse gene95 protein (SEQ ID NO: 5), the first non-human mammalian homolog of gene95. The sequence shares approximately 76% sequence identity across the full length of the protein with human gene95. Human and mouse amino acid sequences are aligned in Figure 6. Shared amino acids are indicated, along with conservative and non-conservative changes. Additional investigations of short nucleic acid sequence segments from other mammals indicate that at the nucleotide level, mammalian species share a generally conserved gene95 sequence. Specifically:
  • Human:Cow 514/565 (90%) identical based on overlapping sequence Human:Rat 338/401 (84%) identical based on overlapping sequence Human:Pig 228/265 (86%), identical based on overlapping sequence Human:Mouse 266/307 (86%) identical based on overlapping sequence
  • Expression pattern Based on EST evidence, the gene is shown to be expressed in the following tissues and cell lines: teratocarcinoma, brain, placenta, ovarian tumor, lymphoma, melanoma, neuroblastoma.
  • the data of Examples 2 and 3 confirm expression in a wide range of tissues.
  • Mutation 1 found in the family BC-11M, was identified as a 1802T>G
  • Mutation 2 from an individual in the NL-003 family with HDL level ⁇ 5 th percentile comprises a 1706C1707 insertion SEQ ID NO: 8. The insert is in a second base of codon for Q436 resulting in Q436P and 39 additional unique amino acids producing a premature stop codon, 475aa total (SEQ ID NO: 9 and counting from the methionine at residue 14). Mutation 2 is also observed in an individual from family NL-120 with HDL ⁇ 5 th percentile. Mutation 2 was not observed in 228 control chromosomes of similar ethnicity. Alignments of the amino acid sequence of mutation 1 and mutation 2 with the wild-type amino acid sequence of human gene95 is set out in Figure 7.
  • cSNPs Single Nucleotide Polymorphisms of the coding region (cSNPs) of gene95 and other polymorphisms have been identified and are set out in Table 1. These cSNPs result in the amino acid changes identified, if any. Other cSNPs and polymorphisms in exonic or intronic regions of gene95 can also be identified by those skilled in the art.
  • the nucleotide sequences disclosed herein may represent less than the full genomic sequence. Such genes and cDNA sequences are still considered corresponding sequences because they both encode similar RNA sequences. Thus, by way of non-limiting example only, a gene that encodes an RNA transcript, which is then processed into a shorter mRNA, is deemed to encode both such RNAs and therefore encodes an RNA complementary to (using the usual Watson-Crick complementarity rules), or that would otherwise be encoded by, a cDNA (for example, a sequence as disclosed herein).
  • sequences disclosed herein correspond to genes contained in the cells and are used to determine relative levels of expression because they represent the same sequences or are complementary to RNAs encoded by these genes.
  • genes also include different alleles and splice variants that may occur in the cells used in the processes of the invention.
  • the polynucleotides such as the gene sequences disclosed herein, for use in the screening assays of the invention "correspond to" gene95 if the polynucleotide encodes an RNA (processed or unprocessed, including naturally occurring splice variants and alleles) that is at least 50% identical, preferably at least 70%, 80%, 90% identical, and more preferably at least 95%o, or 98% identical to, and especially having the sequence of, an RNA that would be encoded by, or be complementary to, such as by hybridization with, a polynucleotide having SEQ ID NO: 3.
  • RNA processed or unprocessed, including naturally occurring splice variants and alleles
  • genes including sequences at least 50% identical to SEQ ID NO: 3, preferably at least about 70%, 80%, 90% identical to such a sequence, more preferably at least about 98% identical to such sequence and most preferably comprising such sequences as are specifically contemplated by all of the processes of the present invention as being genes that correspond to these sequences.
  • sequences encoding the same polypeptides and proteins as any of these sequences, regardless of the percent identity of such sequences are also specifically contemplated by any of the methods of the present invention that rely on any or all of said sequences, regardless of how they are otherwise described or limited. Thus, any such sequences are available for use in carrying out any of the methods disclosed according to the invention.
  • Such sequences also include any open reading frames, as defined herein, present within gene95.
  • Such sequences include the mutant gene95 sequences of SEQ ID NO: 6 and SEQ ID NO: 8, and sequences containing the alternative exons shown in Figure 5.
  • the present invention encompasses an isolated polynucleotide comprising a polynucleotide sequence or the full complement of this polynucleotide sequence, wherein the polynucleotide sequence is at least 65%, preferably at least 75%, more preferably at least 85%, especially at least 90%, most preferably 95%, or even 98%, identical to SEQ ID NO: 3, with the sequence of SEQ ID NO: 3 especially preferred.
  • the invention also includes an isolated polynucleotide comprising a polynucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 4.
  • the invention includes all those proteins, polypeptides and amino acid sequences corresponding to
  • sequences corresponding to SEQ ID NO: 4 include any full length protein or fragment thereof which retains a biological activity of gene95 protein. Such sequences are preferably at least about 50% identical to SEQ ID NO: 4, more preferably about 60%, 70%, 80% and most preferably at least about 90%, or 95%, identical to SEQ ID NO: 4. Such sequences include any ortholog or homolog of gene95 protein from any organism, preferably a eukaryote, more preferably a mammal, most preferably a rodent or human; and any amino acid sequence having at least about 50%, 60%, 70%, 80% and most preferably at least about 90% sequence identity thereto. Such sequences include mutant sequences SEQ ID NO: 7 and SEQ ID NO: 9, sequences corresponding to alternative open reading frames of gene95 nucleotide sequences, and sequences found in the alternatively spliced exons in Figure 5.
  • the present invention includes an isolated polypeptide comprising an amino acid sequence having at least 65%, preferably at least 75%, more preferably at least 85%, especially at least 90%, most preferably 95%, or even 98%, identity with the amino acid sequence set forth in SEQ ID NO: 4, wherein a polypeptide comprising the sequence of SEQ ID NO: 4 is especially preferred.
  • the present invention also relates to nucleic acid vector comprising such an isolated polynucleotide and a recombinant host cell comprising such a vector.
  • the present invention also encompasses a method for producing the polypeptide of SEQ ID NO: 4 comprising culturing the host cell of claim 49 under conditions supporting production of the polypeptide, methods of which are all well known to those skilled in the art in light of the disclosure set forth herein.
  • the present invention provides screening assays using gene95 gene and/or protein for use in identifying therapeutic agents, especially agents antagonistic to low HDL levels.
  • One such protocol involves the screening of chemical agents for ability to modulate, either upward or downward, the activity of gene95 so as to elevate HDL activity, such as by increasing HDL levels, especially plasma levels, in an animal, including humans.
  • Agents that alter the activity of the gene95 gene, or active fragments or portions of it, or that may modulate the activity of polypeptides encoded by gene95, or polypeptides that act as transcription factors to modulate the activity of such genes, or other related gene segments, such as enhancers or other regulatory genetic elements that modulate the activity of gene95, acting either in cis or trans fashion, are thereby identified and may prove useful in preventing, treating, or otherwise ameliorating, low HDL levels, or the effects of low HDL levels or diseases related to low HDL levels, such as by ameliorating reverse cholesterol transport or other lipid related processes, and/or for diseases such as cardiovascular disease, atherosclerosis, and other diseases.
  • compositions and methods for treating patients having low HDL-C, vascular disease, dyslipidemia, atherosclerosis or a related disorder, or for ameliorating reverse cholesterol transport in the body by administering compounds that modulate biological activity or expression of gene95.
  • the present invention specifically contemplates screening assays, such as where a large number of compounds are to be screened for activity in modulating therapeutic target biological activity.
  • modulation may include either an increase or a decrease in therapeutic target biological activity.
  • the invention also provides assays for the identification of such therapeutic compounds and their analogs.
  • Compounds that modulate the biological activity of gene95 gene or protein are considered useful in the invention.
  • Exemplary screening assays (in vitro or in vivo) and computational assays (in silico) for the identification of such compounds are detailed below.
  • the screening assays of the invention simplify the evaluation, identification and development of therapeutic agents for the treatment and prevention of low HDL and/or vascular diseases, dyslipidemias or related disorders.
  • the screening methods provide a facile means for selecting natural product extracts or synthetic compounds of interest from a large population (i.e. a chemical library) which are further evaluated and condensed to a few active core structures. Multiple analogs of such core structures may be developed and tested to identify those preferred analogs which have improved characteristics as therapeutic agents.
  • the present invention also relates to a method for identifying an agent that modulates the activity of a polypeptide whose activity alters high density lipoprotein (HDL)-activity, comprising: a) contacting a candidate compound with a polypeptide encoded by a polynucleotide corresponding to gene95 under conditions facilitating such activity; and b) determining a change in the biological activity of said polypeptide as a result of said contacting; wherein said change in activity identifies the test compound as an agent that modulates said polypeptide biological activity.
  • HDL high density lipoprotein
  • the change in biological activity in step (b) is a decrease or increase in activity of the polypeptide.
  • the activity is measured by measuring the activity of an enzyme, such as where the polypeptide itself has enzyme activity that can be directly or indirectly assayed. Such assays may be conducted in vitro or in vivo.
  • said polypeptide has the amino acid sequence of SEQ ID NO: 4; in an alternative embodiment, said polynucleotide has SEQ ID NO: 3.
  • the polypeptide is present in a cell extract, a liposome or an intact cell.
  • the present invention specifically contemplates embodiments in which the cell is a recombinant cell line containing a heterologous gene95 construct.
  • said cell or extract is engineered by other than genetic engineering, such as where the activity of a polypeptide is to be enhanced and the cell has been engineered to contain, or have on its surface, said polypeptide but wherein the polypeptide is present due to physical insertion of the polypeptide into the membrane or cytoplasm of the cell and not through expression of a gene contained in the cell.
  • the present invention also relates to a method for identifying an agent that modulates a Gene95 activity, comprising: a) contacting a test compound with a polypeptide encoded by a polynucleotide corresponding to gene95 under conditions supporting an activity of said polypeptide; and b) determining a change in the activity of the polypeptide as a result of said contacting; wherein said change in activity identifies the test compound as an agent that modulates a Gene95 activity.
  • Such determined change in activity in step (b) may be a decrease or an increase in activity.
  • the activity is measured by measuring the activity of an enzyme.
  • the polypeptide is present in a lipid bilayer, including where this lipid bilayer is part of a liposome.
  • the polypeptide may be part of an intact cell, such as where the intact cell is a cell that has been engineered to comprise said polypeptide, such as where the intact cell is a recombinant cell that has been genetically engineered to express said polypeptide, preferably where the cell does not express said polypeptide absent said engineering.
  • the intact cell is preferably a mammalian cell.
  • the present invention also relates to a method for identifying an HDL- enhancing agent, comprising administering to an animal an effective amount of an agent found to have modulating activity using any of the assays disclosed herein and detecting an increase in plasma HDL activity in said animal due to said administering thereby identifying an agent useful in enhancing HDL activity.
  • said animal exhibits low HDL activity prior to administering said agent.
  • the HDL- enhancing activity is an increase in HDL level in said animal, most preferably an increase in plasma HDL level and preferably where said animal is a human patient.
  • the present invention additionally relates to a method for treating a low-HDL related disorder in an animal afflicted with said disorder comprising administering to said animal an effective amount of an agent found to have HDL-enhancing activity using any of the assays of the invention.
  • the animal to be treated is a human patient.
  • the disorder to be treated is selected from the group consisting of low HDL diseases, vascular diseases and dyslipidemias.
  • the agents identified according to the processes of the invention are also useful for treating or preventing coronary artery disease, regardless of the HDL status of the patient. For example, a patient with normal HDL levels who has a family history of coronary artery disease would still be advised to take a therapeutic agent according to the invention in order to elevate HDL levels and further reduce the risk of coronary artery disease. Thus, the patient does not need to have a dyslipidemia in order to be eligible for treatment according to the invention.
  • screening methods of the invention involve screening any number of compounds for therapeutically active agents by employing any number of in vitro or in vivo experimental systems. Exemplary methods useful for the identification of such compounds are detailed herein.
  • the methods of the invention simplify the evaluation, identification and development of active agents for the treatment and prevention of low HDL levels as well as cardiovascular disease (CVD) and dyslipidemias.
  • the screening methods provide a ready means for selecting natural product extracts or compounds of interest from a large population which are further evaluated and condensed to a few active and selective materials. Positive candidates from this pool are then purified and evaluated in the methods of the invention to determine their HDL-raising, anti-CVD or anti-dyslipidemia activities or both.
  • the positive candidates may be used directly as therapeutic agents, or they may provide informative structures for structure-activity relationship (SAR) analysis and development of further analogs which then become the preferred therapeutic agents.
  • SAR structure-activity relationship
  • Gene 95 is to maintain HDL levels in humans, the specific mechanism of action of Gene 95 remains to be established. Without being bound to any theory for a mechanism of action, the inventors suggest that Gene 95 may function as a sulfurtransferase, or similar type enzyme. This is based on the comparison of the Rhodanese domain found in the protein. Rhodanese domains may be classified as active for sulfurtransferase activity, active for phosphatase activity or catalytically inactive. Human and mouse G95 contain consensus for sulfurtransferase within the rhodanese domain. Possible consensus for phosphatase within rhodanese domain is found in the human but not conserved in mouse G95. In addition, one other human gene with this consensus has been annotated as a sulfurtransferase activity.
  • thioredoxin binding protein Txnip is known to be involved in lipid metabolism based on the hyperlipidemic mouse phenotype.
  • screening assays employing a gene 95 sulfurtransferase biological activity may be designed using a known substrate for sulfurtransferases, such as cyanide, thioredoxin and dihydrolipoate.
  • screening assays may be designed based on previously disclosed sulfurtransferase assays.
  • the assay measures conversion of thiosulfate and cyanide to sulfite and thiocyanate.
  • the assay measures conversion of thiosulfate and thioredoxin to sulfite and thioredoxinpersulfide.
  • Compounds which agonize or antagonize these conversions via Gene 95 interaction are modulators of the invention.
  • Functional assays may be based on the activity of a polypeptide encoded by one or more of the polynucleotides disclosed herein as corresponding to gene95, including candidates with high homology thereto, such as polynucleotides at least 90% or 95% identical to such genes or polypeptides with high homology to the polypeptides encoded by said genes.
  • Such assays may employ drug screening technology such as (but not limited to) the ability of various dyes to change color in response to changes in assay conditions resulting from the activity of the polypeptides.
  • Drug screening assays can also be based upon the ability of gene95 polypeptide to interact with other proteins.
  • Such interacting proteins can be identified by a variety of methods known in the art, including, for example, radioimmunoprecipitation, co-immunoprecipitation, co-purification, and yeast two-hybrid screening.
  • the ability of test compounds to agonize or antagonize protein-protein interactions is a standard type of screening assay that may be employed. Such interactions can be assayed by means including but not limited to fluorescence polarization or scintillation proximity methods.
  • Drug screens can be based upon a function or feature apparent upon creation of a transgenic or knockout mouse, or upon overexpression of the protein or protein fragment in mammalian cells in vitro.
  • mammalian (e.g., human) gene95 polypeptides in yeast or C. elegans allows for screening of candidate compounds in wild-type and mutant backgrounds, as well as screens for mutations that enhance or suppress a low HDL phenotype. Modifier screens can also be performed in transgenic or knock-out mice.
  • Gene95 suggest more specialized assays that may be employed.
  • the putative phosphorylation sites suggest that an assay which measures a test compound's propensity to influence the rate, amount or timing of phosphorylation of gene95 would be a useful modulator of the invention, and a potential therapeutic agent or analog thereof for the diseases indicated herein.
  • genes95 which can be exploited for use in screening include the N-glycosylation site, the Glycosaminoglycan attachment site; the 4 cAMP- and cGMP-dependent protein kinase phosphorylation sites; the 12 Protein kinase C phosphorylation sites; the 8 Casein kinase II phosphorylation sites; the 8 N-myristoylation sites; the Zinc finger C2H2 type domain; and the Cysteine-rich region.
  • the present invention relates to a method for identifying an agent that modulates the activity of a polynucleotide whose expression alters high density lipoprotein (HDL)-activity in vivo, comprising: a) contacting a test compound with a polynucleotide corresponding to gene95 under conditions facilitating expression of the polynucleotide; and b) determining a change in the expression of the polynucleotide as a result of said contacting; wherein said change in expression identifies the test compound as an agent that modulates the activity of a polynucleotide whose expression alters high density lipoprotein (HDL)-activity.
  • HDL high density lipoprotein
  • the change in expression in step (b) may be a decrease or increase in expression of said polynucleotide or gene.
  • the present invention relates to a method for identifying an agent that modulates Gene95 activity, comprising: a) contacting a test compound with a genetic construct comprising a reporter gene operably linked to a Gene95 promoter under conditions supporting transcription of said reporter gene; b) determining a change in transcription of the reporter gene as a result of said contacting wherein a change in said transcription indicates that the test compound is an agent that modulates Gene95 activity.
  • Such determined changes may be an increase or decrease in the recited transcription and wherein transcription is determined by measuring the amount of an expression product encoded by said reporter gene, such expression product including either an RNA or a polypeptide.
  • the reporter gene may be present in a liposome or in an intact cells, such as a mammalian cell.
  • Preferred embodiments of such methods include use of a mammalian Gene95 promoter, such as a human promoter, preferably that shown in SEQ ID NO: 15, or a mouse promoter, preferably the promoter sequence in SEQ ID NO: 14.
  • the reporter gene is commonly a gene whose expression is easily measured and will be other than Gene95 itself, although the latter is not excluded for use as a reporter gene.
  • Such a process is especially useful for identifying agents effective against low HDL levels and disorders, and symptoms thereof.
  • agents or their chemical analogs are also useful for modulating gene95 gene or protein and/or for treatment or prophylaxis of cardiovascular disease.
  • An example of a construct comprising a human Gene95 promoter sequence is shown in SEQ ID NO: 15, wherein the promoter sequence (about the first 1500 bases) is at the start of the sequence and is followed by exon 1 (starting at residue 1502) after which is intron 1 with exon 2 at the end of the sequence, while a sequence that incorporates a mouse promoter (about 1500 nucleotide residues) is shown in SEQ ID NO: 14, with the promoter at the beginning of the sequence, then followed by exonl (starting at residue 1501), followed by intron 1 with exon 2 at the end of the sequence.
  • the exonic sequences were found in mRNA.
  • the present invention encompasses such exon and promoter sequences.
  • the invention provides a method for computationally identifying a compound for modulating HDL levels and/or treating a vascular disease or dyslipidemia.
  • the method involves (a) determining the active site of the gene95 protein (i.e. through X-Ray crystallography or other techniques); and (b) through computational modeling, identifying a compound which interacts with the active site, thereby identifying a compound, or its analog, as a compound which is useful for modulating HDL levels and/or treating a vascular disease, dyslipidemia or a related disorder.
  • the present invention further relates to a method for identifying a therapeutic agent, comprising: a) contacting a chemical agent with a polynucleotide corresponding to gene95 under conditions supporting expression of said polynucleotide; b) determining a change in the expression of said polynucleotide as a result of said contacting; wherein a change in said expression identifies a therapeutic agent.
  • the present invention encompasses a method for identifying a therapeutic agent that modulates the activity of a polypeptide that affects high density lipoprotein (HDL)-activity in vivo, comprising: a) contacting a test compound with a polypeptide encoded by a polynucleotide corresponding to gene95 under conditions supporting an activity of said polypeptide; and b) determining a change in the activity of said polypeptide as a result of said contacting; wherein a change in said activity identifies the test compound as a therapeutic agent that modulates the activity of a polypeptide that affects HDL activity.
  • HDL high density lipoprotein
  • polypeptide corresponds to
  • SEQ ID NO: 4 and/or the polynucleotide corresponds to SEQ ID NO: 3
  • Gene95 polypeptide preferably of mammals, most preferably of rodent or human, can be used as an antigen to raise antibodies, including monoclonal antibodies. Such antibodies will be useful for a wide variety of purposes, including but not limited to therapeutic uses for modulating gene95 biological activity, functional studies and the development of drug screening assays and diagnostics. Monitoring the influence of agents (e.g., small organic compounds) on the expression or biological activity of gene95 polypeptide identified according to the invention can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase or decrease gene expression, protein levels, or biological activity can be monitored in clinical trails of subjects exhibiting low HDL levels due to inadequate gene expression, protein levels, or biological activity.
  • agents e.g., small organic compounds
  • the effectiveness of an agent determined by a screening assay to modulate expression of gene95, as well as structurally and functionally related genes, including genes with high homology thereto, and including protein levels, or biological activity can be monitored in clinical trials of subjects exhibiting decreased altered gene expression, protein levels, or biological activity.
  • the expression or activity of the genes or polypeptides disclosed herein and, preferably, other genes that have been implicated in, for example, cardiovascular disease can be used to ascertain the effectiveness of a particular drug.
  • genes that are modulated in cells by treatment with an agent e.g., compound, drug or small molecule
  • an agent e.g., compound, drug or small molecule
  • polypeptides that modulate that activity of any of such genes e.g., identified in a screening assay as described herein
  • cells can be isolated and RNA prepared and analyzed for the levels of expression of gene95 and other genes implicated in similar or related disorders.
  • the levels of gene expression can be quantified by Northern blot analysis or RT-PCR, or, alternatively, by measuring the amount of protein produced, by one of a number of methods known in the art, or by measuring the levels of biological activity of polypeptides encoded thereby or other genes.
  • the gene expression can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.
  • the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, anti-gene95 antibody, antisense molecule, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) including the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of HDL activity or level of expression of gene95 protein, mRNA, or genomic DNA in the pre-administration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of gene95 protein, mRNA, or genomic DNA or HDL in the post-administration samples; (v) comparing the level of expression or activity of said protein, mRNA, or genomic DNA in the pre-administration sample with that of the corresponding post administration sample or samples; and (vi) altering the administration of the agent to the subject
  • an agent
  • increased administration of the agent may be desirable to increase the expression or activity of gene95 or its encoded polypeptide, or to increase HDL-activity, such as plasma HDL-level, to higher levels than detected, i.e., to increase the effectiveness of the agent.
  • decreased administration of the agent may be desirable to decrease expression or activity of the polypeptide or gene where excess expression contributes to lowering of HDL activity or levels.
  • the gene95 genes disclosed herein as being involved in HDL regulation can be used, or a fragment thereof can be used, as a tool to express a protein, where such genes encode a proteirr, in an appropriate cell in vitro or in vivo (gene therapy), or can be cloned into expression vectors which can be used to produce large enough amounts of protein to use in in vitro assays for drug screening.
  • Expression systems which may be employed include baculovirus, herpes virus, adenovirus, adeno-associated virus, bacterial systems, and eucaryotic systems such as CHO cells. Naked DNA and DNA-liposome complexes can also be used.
  • Assays of such activity include binding to intracellular interacting proteins, interaction with a protein that up-regulates gene or polypeptide activity, interaction with HDL particles or constituents, interaction with other proteins which facilitate interaction with HDL or its constituents, and measurement of cholesterol efflux.
  • assays may be based upon the molecular dynamics of macromolecules, metabolites and ions by means of fluorescent-protein biosensors.
  • the effect of candidate modulators on expression or activity may be measured at the level of protein production using the same general approach in combination with standard immunological detection techniques, such as Western blotting or immunoprecipitation with a specific antibody.
  • useful cholesterol- regulating or anti-CVD therapeutic modulators are identified as those which produce an change in activity that correlates with increased HDL levels, especially in the plasma of a test subject.
  • Candidate modulators may be purified (or substantially purified) molecules or may be one component of a mixture of compounds (e.g., a combinatorial library or an extract or supernatant obtained from cells).
  • a mixed compound assay gene expression is tested against progressively smaller subsets of the candidate compound pool (e.g., produced by standard purification techniques, e.g., HPLC or FPLC; Ausubel et al.) until a single compound or minimal compound mixture is demonstrated to modulate gene or protein activity or expression in a manner having a beneficial effect on HDL levels.
  • Specific compounds which will modulate the gene expression or gene transcript levels in a cell of gene95 include antisense nucleic acids, ribozymes and other nucleic acid compositions and sequence specific binding compounds which specifically hybridize with said gene (including exons or introns of such genes) or any RNA transcript of gene95. These specific compounds are compounds of the invention, and are useful for treating the diseases discussed previously. Design and manufacturing of such compounds are easily achieved by those skilled in the art based on the disclosures of the instant specification.
  • Specific compounds which modulate the activity of gene95 polypeptide include antibodies (polyclonal or monoclonal) which specifically bind to an epitope of said polypeptide. These specific compounds are compounds of the invention, and are useful for treating the diseases discussed previously. Design and manufacturing of such compounds are well known to those skilled in the art.
  • Antibodies and antibody fragments that specifically recognize one or more epitopes of gene95, or epitopes of conserved variants of gene95, or peptide fragments of the gene95 are also encompassed by the invention.
  • Such antibodies include but are not limited to polyclonal antibodies, monoclonal antibodies (MAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. These may be used to treat any of the disorders disclosed herein.
  • the method includes immunizing a transgenic non-human animal, e.g., a transgenic mouse, having a genome comprising a human heavy chain transgene and a human light chain transgene, with a purified or enriched preparation of the gene95 protein, or a fragment thereof.
  • B cells e.g., splenic B cells
  • myeloma cells to form immortal, hybridoma cells that secrete human monoclonal antiboides against the gene95 protein.
  • Humanized antibodies may also be produced, for example by replacing an immunogenic portion of an antibody with a corresponding, but non- immunogenic portion (i.e. chimeric antibodies)
  • a corresponding, but non- immunogenic portion i.e. chimeric antibodies
  • various host animals may be immunized by injection with the gene95, a gene95 peptide (e.g., one corresponding the a functional domain of the protein), truncated gene95 polypeptides (gene95 in which one or more domains has been deleted), functional equivalents of the gene95 or mutants of the gene95.
  • Such host animals may include but are not limited to rabbits, mice, goats and rats, to name but a few.
  • adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum.
  • BCG Bacille Calmette-Guerin
  • HuMab mice can be immunized with a preparation of gene95 or a fragment thereof, which has been purified or enriched according to any standard method.
  • HuMab mice contain a human immunoglobulin gene miniloci that encodes unrearranged human heavy (mu and gamma) and kappa light chain immunoglobulin sequences, together with targeted muattions that inactivate the endogenous mu and kappa chain loci (Lonberg, N. et al. (1994) Nature. 368(6474): 856-859.). These mice exhibit reduced expression of mouse IgM or kappa, and in response to immunization, the introduced human heavy and light chain transgenes undergo class switching and somatic mutation to generate high affinity human IgGkappa monoclonals.
  • mice are 6 - 16 weeks of age upon the first immunization.
  • Initial immunization is intraperitoneal (IP) with antigen in complete Freund's adjuvant, followed by every other week IP immunizations (up to a total of 6) with antigen in incomplete Freund's adjuvant.
  • IP intraperitoneal
  • the immune response can be monitored over the course of the immunization protocal with plasma samples obtained by retroorbital bleeds.
  • the plasma can be screened, for example by ELISA or flow cytometry, and mice with sufficient titers of anti-gene95 human immunoglobulin can be used for fusions.
  • Mice can be boosted intravenously with antigen 3 days before sacrifice and removal of the spleen. It is expected that 2-3 fusions for each antigen are needed for success.
  • mice splenocytes For generation of hybrodiomas producing human monoclonal antibodies to gene95, the mouse splenocytes are first isolated and fused with PEG to a mouse myeloma cell line based upon standard protocols. The resulting hybridomas are then screened for the production of antigen-specific antibodies. For example, single cell suspensions of splenic lymphocytes from immunized mice are fused to one-sixth the number of P3X63-Ag8.653 nonsecreting mouse myeloma cells (ATCC, CRL 1580) with 50% PEG.
  • PEG P3X63-Ag8.653 nonsecreting mouse myeloma cells
  • Cells are plated at approximately 2 X 10 5 in flat bottom microtiter plate, followed by a two week incubation in selective medium containing 20% fetal calf serum, 18% "653" conditioned media, 5% origen (IGEN), 4 mM L-glutamine, 1 mM L- glutamine, 1 mM sodium pyruvate, 5 mM HEPES, 0.055 mM 2- mercaptoethanol, 50 units/ml penicillin, 50 mg/ml streptomycin, 50 mg/ml gentamycin and 1X HAT (Sigma; the HAT is added 24 hours after the fusion). After two weeks, cells are cultured in medium in which the HAT is replaced with HT.
  • selective medium containing 20% fetal calf serum, 18% "653" conditioned media, 5% origen (IGEN), 4 mM L-glutamine, 1 mM L- glutamine, 1 mM sodium pyruvate, 5 mM HEPES,
  • selected hybridomas can be grown in two-litre spinner-flasks for monoclonal antibody purification.
  • Supernatants can be filtered and concentrated before affinity chromatography with protein A-sepharose. (Pharmacia, Piscataway, NJ).
  • Eluted IgG can be checked by gel electrophoresis and high performance liquid chromatography to ensure purity.
  • the buffer solution can be exchanged into PBS, and the concentration can be determined by OD 2 so using 1.43 extinction co-efficient.
  • the monolconal antibodies can be aliquoted and stored at -80°C until required for use according to the methods of the invention.
  • compositions which can serve to increase HDL levels and/or treat the diseases discussed herein are a nucleic acid construct comprising a gene95 gene and combined into a gene-therapy delivery vehicle.
  • Such vehicles may be simple aqueous buffers (for naked DNA delivery), viral based vehicles or non-viral (especially lipid-based) vehicles.
  • These specific compounds are compounds of the invention, and are useful for treating the diseases discussed previously. Design and manufacturing of such compounds easily achieved by those skilled in the art based on the instant specification.
  • Agonists, antagonists, or mimetics found to be effective at modulating the level of cellular expression or activity may be confirmed as useful in animal models (for example, primates, mice, pigs, dogs, rabbits, or chickens).
  • animal models for example, primates, mice, pigs, dogs, rabbits, or chickens.
  • the compound may ameliorate the low HDL levels of mouse or chicken hypoalphalipoproteinemias.
  • a compound that promotes an increase in expression or activity of a gene or polypeptide that has the function of facilitating HDL production is considered particularly useful in the invention; such a molecule may be used, for example, as a therapeutic to increase the level or activity of HDL and thereby treat a low HDL condition in an animal (for example, a human).
  • the invention permits the identification of other HDL-related genes that may play a role in HDL-activity regulation and thus mutations in such genes may be important in studying other genes that are involved in HDL levels.
  • mutations that serve to stabilize gene95 proteins that otherwise contribute to elevating HDL levels have value.
  • Such mutations can be incorporated into any protein therapy or gene therapy undertaken for the treatment of low HDL-C levels.
  • compounds that increase the stability of a wild-type gene95 polypeptide or decrease its catabolism may also be useful for the treatment of low HDL-C or any other condition resulting from low HDL levels.
  • Mutant forms of gene95 identified herein are also useful for this purpose. Further mutations and compounds can be identified using the methods described herein.
  • cells expressing a gene95 polypeptide having a mutation are transiently metabolically labeled during translation and the half-life of the said polypeptide is determined using standard techniques. Mutations that increase the half-life of the polypeptide are ones that increase protein stability. These mutations can then be assessed for HDL-related biological activity. They can also be used to identify proteins that affect the stability of corresponding mRNA or other proteins. One can then assay for compounds that act on these factors or on the ability of these factors to bind such polypeptides. In another example, cells expressing a wild-type gene95 polypeptide are transiently metabolically labeled during translation, contacted with a candidate compound, and the half-life of the polypeptide is determined using standard techniques. Compounds that increase the half-life of the polypeptide are useful compounds in the present invention.
  • treatment with an agonist of the invention may be combined with any other HDL-raising or anti-CVD or anti-dyslipidemia therapies, or other conditions which require HDL management.
  • the assays of the invention comprise protein based assays.
  • the polypeptide encoded by the gene95 gene can be used in an assay to determine its ability to bind another protein (including, but not limited to, proteins found to specifically interact with proteins known to be involved in HDL-activity. Some examples would include ABCA1 protein and apolipoprotein. The effect of a compound on that binding is then determined.
  • the gene95 polypeptide (or a polypeptide fragment thereof or an epitope-tagged form or fragment thereof) is harvested from a suitable source (e.g., from a prokaryotic expression system, eukaryotic cells, a cell-free system, or by immunoprecipitation from expressing cells).
  • a suitable source e.g., from a prokaryotic expression system, eukaryotic cells, a cell-free system, or by immunoprecipitation from expressing cells.
  • the polypeptide is then bound to a suitable support (e.g., nitrocellulose or an antibody or a metal agarose column in the case of, for example, a his-tagged form of said polypeptide). Binding to the support is preferably done under conditions that allow proteins associated with the polypeptide to remain associated with it.
  • Such conditions may include use of buffers that minimize interference with protein-protein interactions.
  • the binding step can be done in the presence and absence of compounds being tested for their ability to interfere with interactions between said polypeptide and other molecules.
  • other proteins e.g., a cell lysate
  • the immobilized polypeptide is then washed to remove proteins or other cell constituents that may be non-specifically associated with it the polypeptide or the support.
  • the immobilized polypeptide is then dissociated from its support, and proteins bound to it are released (for example, by heating), or, alternatively, associated proteins are released from the polypeptide without releasing the latter polypeptide from the support.
  • the released proteins and other cell constituents can be analyzed, for example, by SDS-PAGE gel electrophoresis, Western blotting and detection with specific antibodies, phosphoamino acid analysis, protease digestion, protein sequencing, or isoelectric focusing. Normal and mutant forms of such polypeptide can be employed in these assays to gain additional information about which part of the polypeptide a given factor is binding to. In addition, when incompletely purified polypeptide is employed, comparison of the normal and mutant forms of the protein can be used to help distinguish true binding proteins.
  • such assay is performed using a purified or semipurified protein or other molecule that is known to interact with a polypeptide encoded by a polynucleotide corresponding to gene95.
  • This assay may include the following steps. 1. Harvest the gene95 polypeptide and couple a suitable fluorescent label to it;
  • FRET Fluorescent Resonance Energy Transfer
  • a suitable FRET donor e.g.,. nitro-benzoxadiazole (NBD)
  • Quenching and FRET assays are related. Either one can be applied in a given case, depending on which pair of fluorophores is used in the assay.
  • Gene95 may act by altering membrane permeability, such as the permeability of membranes to ions. Such activity may be assayed for using vesicles, such as liposomes or intact cells, wherein such structures comprise gene95 polypeptides of the invention, which polypeptides are expressed in such vesicle, preferably an intact cell, such as a mammalian recombinant cell, and the permeability of the membrane of the cell is determined in the presence or absence of such expression. In the same way, such permeability can then be assayed in the presence and absence of chemical agents known to modulate the activity of gene95. Thus, the utility of these agents in enhancing the activity of proteins known to affect such membrane transport can be readily determined. In the same way, the ability of these agents to affect the transport of other molecules, such as lipids, especially HDL, across such membranes is likewise readily determined.
  • the test cell such as the aforementioned mammalian recombinant cell expressing gene95, or a polynucleotide corresponding to such gene is loaded with a reporter molecule (such as a fluorescent ion indicator whose fluorescent properties change when it binds a particular ion) that can detect ions, or alternatively, the external medium is loaded with such a molecule.
  • a reporter molecule such as a fluorescent ion indicator whose fluorescent properties change when it binds a particular ion
  • the external medium is loaded with such a molecule.
  • a molecule which exhibits differential properties when it is inside the vesicle compared to when it is outside the vesicle may be used. For example, a molecule that has quenching properties when it is at high concentration but not when it is at another low concentration would be suitable.
  • the effect of transport of ions (Ca, K, Na, metals and the like) across the membrane can be measured if the effect is to quench or unquench a dye which has been loaded into the medium or into the cell.
  • the movement of the charged molecule (either its ability to move or the kinetics of its movement) in the presence or absence of a compound being tested for its ability to affect this process can be determined.
  • uptake of radioactive isotopes into or out of a vesicle can be measured.
  • the vesicles are separated from the extravesicular medium and the radioactivity in the vesicles and in the medium is quantitated and compared.
  • the present invention also relates to assays that may employ transcription factors for one or more of the genes disclosed herein.
  • the association between the polynucleotide to be tested and the binding factor may be assessed by means of any system that discriminates between protein-bound and non-protein-bound DNA (e.g., a gel retardation assay).
  • the effect of a compound on the binding of a factor to such DNA is assessed by means of such an assay.
  • in vitro assays in which the regulatory regions of the gene are linked to reporter genes can also be performed.
  • such polynucleotide is one that corresponds to gene95, most preferably wherein said polynucleotide has SEQ ID NO. 3.
  • the invention includes recombinant cell lines containing a gene95 gene construct. Recombinant cell lines expressing the corresponding protein are tested to identify a relevant biological activity of the protein that can be modulated by exposure to test compound(s). Compound(s) are systematically screened to evaluate whether they modulate the identified biological activity and those that effectively do so are then therapeutic agents, or analogs thereof, according to the invention.
  • Recombinant cell lines are also preferred for the preparation of purified protein, if a purified protein assay is desired. Those skilled in the art are capable of producing recombinant cell lines and extracting protein fractions containing highly purified proteins. These samples can be used in a variety of binding assays to identify compounds which interact with the proteins. Compounds that interact are therapeutic agents of the invention, or analogs thereof.
  • the invention also comprises the upstream untranslated regions and promoter regions of gene95.
  • a segment of the promoter region is included in Figure 5. Larger portions of this promoter region can be now be identified by those skilled in the art, using this disclosure.
  • the 5'UTR (untranslated region) is disclosed in SEQ ID NO. 3, 6, 8 and Figure 5.
  • genomic or untranslated regions may be included in plasmids which are used in assays to identify compounds which modulate the expression of the identified gene.
  • the upstream genomic region is ligated to a reporter gene, and incorporated into an expression plasmid.
  • the plasmid is transfected into a cell, and the recombinant cell is exposed to test compound(s). Those compounds which increase or decrease the expression of the reporter gene are then modulators of the gene/protein, and are considered therapeutic agents of the invention.
  • a transport-based assay for such activity can be performed in vivo or in vitro.
  • the assay may be based on any part of the reverse cholesterol transport process that is readily re-created in culture, such as cholesterol or phospholipid efflux.
  • the assay may be based on net cholesterol transport in a whole organism, as assessed by means of a labeled substance (such as cholesterol).
  • fluorescent lipids can be used to measure lipid efflux.
  • a fluorescent precursor, C6-NBD- phosphatidic acid can be used. This lipid is taken up by cells and dephosphorylated by phosphatidic acid phosphohydrolase.
  • the product, NBD-diglyceride is then a precursor for synthesis of glycerophospholipids like phosphatidylcholine.
  • the efflux of NBD-phosphatidylcholine can be monitored by detecting fluorescence resonance energy transfer (FRET) of the NBD to a suitable acceptor in the cell culture medium.
  • FRET fluorescence resonance energy transfer
  • Suitable acceptors include rhodamine-labeled phosphatidylethanolamine, a phospholipid that is not readily taken up by cells.
  • the use of short-chain precursors obviates the requirement for the phospholipid transfer protein in the media.
  • NBD-cholesterol ester can be reconstituted into LDL.
  • the LDL can efficiently deliver this lipid to cells via the LDL receptor pathway.
  • the NBD-cholesterol esters are hydrolyzed in the lysosomes, resulting in NBD-cholesterol that can now be transported back to the plasma membrane and efflux from the cell.
  • the efflux can be monitored by the aforementioned FRET assay in which NBD transfers its fluorescence resonance energy to the rhodamine- phosphatidylethanoline acceptor.
  • Animal models are also useful in the assays of the invention.
  • Compounds identified as having activity in any of the above-described assays are subsequently screened in any available animal model system, including, but not limited to, pigs, rabbits, and chickens, to see if HDL levels are elevated as a result of such compounds being administered in an appropriately effective amount to said animal.
  • Test compounds are administered to these animals according to standard methods.
  • Test compounds may also be tested in mice bearing mutations in interfere with cholesterol transport.
  • compounds may be screened for their ability to enhance an interaction between a polypeptide encoded by a polynucleotide corresponding to gene95 and any HDL particle constituent such as ApoAI, ApoAII, or ApoE.
  • Such cholesterol efflux assay measures the ability of cells to transfer cholesterol to an extracellular acceptor molecule and are usually dependent on the presence of a transporter molecule, such as ABCA1.
  • the genes disclosed herein may play a role in modulating the activity of ABCA1 , such as where a polypeptide encoded by a polynucleotide disclosed herein binds to, and modulates, the activity of ABCA1 or other HDL-related protein.
  • cells are loaded with radiolabeled cholesterol by any of several biochemical pathways (Marcil et al., Arterioscler. Thromb. Vase. Biol. 19:159- 169, 1999).
  • Cholesterol efflux is then measured after incubation for various times (typically 0 to 24 hours) in the presence of HDL3 or purified ApoAI. Cholesterol efflux is determined as the percentage of total cholesterol in the culture medium after various times of incubation. Compounds that modulate cholesterol efflux in this assay may be acting on the gene95 protein target.
  • the cell is a recombinant cell line containing a gene95 construct.
  • the invention also comprises a transgenic animal, such as a mouse, that has had one or both alleles of gene95 inactivated (e.g., by homologous recombination) or conversely, a mouse having one or more additional copies of gene95 or additional mutant copies of gene95.
  • a transgenic animal such as a mouse
  • Such mice represent a useful animal model for screening for compounds that raise HDL-C levels.
  • Such mice are also useful for experimental purposes to determine the role of gene95 in living systems.
  • Such an animal can be produced using standard techniques.
  • the animals having different versions of such genes are useful for further testing of efficacy and safety of drugs or agents first identified using one of the other screening methods described herein.
  • Cells taken from the animal and placed in culture can also be exposed to test compounds. HDL-C levels can be measured using standard techniques, such as those described herein.
  • Compounds first identified as useful in elevating HDL activity using one or more of the assays of the invention may be administered with a pharmaceutically-acceptable diluent, carrier, or excipient, in unit dosage form.
  • Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer such compositions to patients.
  • oral administration is preferred, any appropriate route of administration may be employed, for example, parenteraL. intravenous, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracistemal, intraperitoneal, intranasal, aerosol, or oral administration.
  • Therapeutic formulations may be in the form of liquid solutions or suspension; for oral administration, formulations may be in the form of tablets or capsules; and for intranasal formulations, in the form of powders, nasal drops, or aerosols.
  • a successful gene95 modulating therapeutic agent will meet some or all of the following criteria.
  • Oral availability should be at or above 20% (so that at least 20% is absorbed into the blood stream).
  • Animal model efficacy should be less than about 2 mg/kg and the target human dose between 50 and 250 mg/70 kg, although doses outside of this range may be acceptable.
  • the therapeutic index (or ratio of toxic dose to therapeutic dose) should be greater than 100.
  • the potency (as expressed by IC 50 value) should be less than about 10 ⁇ M, preferably below 1 ⁇ M, and most preferably below 100 nM.
  • the agent should show reversible binding (i.e., competitive inhibition) and should be reasonably selective over unrelated targets, or related targets that cause unwanted side effects.
  • the required dosage should be no more than about once or twice a day or at meal times.
  • Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes.
  • Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds.
  • parenteral delivery systems for agonists of the invention include ethylenevinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
  • Formulations for inhalation may contain excipients, or example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.
  • novel drugs for the treatment of aberrant cholesterol levels and/or CVD or dyslipidemia are identified from large libraries of both natural product or synthetic (or semi-synthetic) extracts or chemical libraries including combinatorial chemical libraries, according to methods known in the art.
  • Those skilled in the field or drug discovery and development will understand that the precise source of test extracts or compounds is not critical to the screening procedure(s) of the invention. Accordingly, virtually any number of chemical extracts or compounds can be screened using the exemplary methods described herein. Examples of such extracts or compounds include, but are not limited to, plant-, fungal-, prokaryotic- or animal-based extracts, fermentation broths, and synthetic compounds, as well as modification of existing compounds.
  • Synthetic compound libraries are commercially available from Brandon Associates (Merrimack, NH) and Aldrich Chemical (Milwaukee, Wl).
  • libraries of natural compounds in the form of bacterial, fungal, plant, and animal extracts are commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceangraphics Institute (Ft. Pierce, FL), and PharmaMar, U.S.A. (Cambridge, MA).
  • natural and synthetically produced libraries are produced, if desired, according to methods known in the art, e.g., by standard extraction and fractionation methods.
  • any library or compound is readily modified using standard chemical, physical, or biochemical methods.
  • the invention further comprises the use of gene95 protein or protein fragments as therapeutic agents, and includes any modified forms of gene95 which retain the biological activity of gene95.
  • These therapeutic agents can be administered to patients in need thereof, such as patients who would benefit by increasing gene95 biological activity either locally, regionally or throughout the body, as administered.
  • Such patients include, but are not limited to, patients suffering from low HDL, dyslipidemia, cardiovascular disease and other disorders.
  • Functional gene95 protein and soluble derivatives thereof, such as peptides corresponding to functional domains of gene95 or modified versions of gene95 protein, can be produced by standard methods known in the art.
  • Administration to patients can be intravenous, oral, intraperitoneal, or by any other method known in the art.
  • Gene expression both comparable and absolute, as well as biological activity, and mutational analysis can each serve as a diagnostic tool for low HDL; thus determination of the genetic subtyping of the gene sequence can be used to subtype low HDL individuals or families to determine whether the low HDL phenotype is related to a given protein function, as with the families used in accordance with the present invention.
  • This diagnostic process can lead to the tailoring of drug treatments according to patient genotype, including prediction of side effects upon administration of HDL increasing drugs (referred to herein as pharmacogenomics).
  • Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual is examined to determine the ability of the individual to respond to a particular agent).
  • agents e.g., drugs
  • the present invention further relates to processes diagnosing the presence of a disorder, especially at its earliest stages, or the risk to a patient of developing such disorders.
  • the present invention relates to a process for diagnosing the presence of a disorder in a patient suspected of being afflicted therewith comprising detecting a mutation in the gene95 gene in the genome of said patient.
  • the present invention relates to such diagnostic processes where the mutation is the mutation in the nucleotide sequence as depicted in SEQ ID NO: 6 and/or SEQ ID NO: 8 and/or Table 1.
  • the mutation is detected in a sample of DNA taken from said patient.
  • a sample may be obtained in any manner commonly used to obtain such sample, such as by blood sample, biopsy or other methods.
  • detecting may be accomplished in vivo, such as where an in situ procedure is used to detect the presence of a mutated gene95 gene or nucleotide sequence in a patient.
  • the disorders that can be so detected are not limited to low HDL, dyslipidemia, cardiovascular disease, and the other disorders thereby included, disclosed previously
  • the present invention relates to a process for diagnosing the presence of an gene95-linked disease in a patient suspected of being afflicted therewith comprising detecting a mutation in the gene95 gene in the genome or mRNA of said patient.
  • the invention relates to such a process wherein said mutation is detected in a sample of DNA taken from the patient, most preferably wherein the mutation is the mutation of SEQ ID NO. 6 or SEQ ID NO. 8 or Table !
  • said detecting is accomplished by determining the ability of a nucleic acid probe comprising at least 15 contiguous nucleotides that are complementary to a mutated portion of the sequence of SEQ ID NO: 1 , most preferably wherein said probe comprises at least 30 contiguous nucleotides, especially where the probe comprises at least 50 contiguous nucleotides.
  • the processes disclosed herein are also useful in determining the risk of a patient in developing one or more of the above disorders, so that the present invention also relates to a process for determining a patient's risk of developing a disorder where said patient is suspected to be at risk thereof, comprising detecting a mutation in the gene95 gene in the genome or mRNA of said patient. Such detection may, in keeping with the foregoing, be by either in vitro or in vivo means.
  • said disorder is low HDL, dyslipidemia and/or cardiovascular disease.
  • the mutation is a mutation in the gene corresponding to SEQ ID NO: 1.
  • detection may be achieved by a variety of methods, but typically involves use of an anti-gene95 antibody in a standard ELISA assay.
  • those skilled in the art may now develop diagnostic tools for detecting mutant or normal gene95 in patient samples, for the diagnosis of various disorders.
  • Agents, or modulators, having a stimulatory or inhibitory effect on the gene95 gene, or gene product can be administered to individuals to treat disorders associated with low HDL-activity or level.
  • the pharmacogenomics i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug
  • Differences in efficacy of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug.
  • the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype.
  • Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the genetic complement of an individual with respect to the genes disclosed herein can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.
  • Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons (Eichelbaum, M., Clin. Exp. Pharmacol. Physiol., 23:983- 985, 1996; Under, M. W., Clin. Chem., 43:254-266, 1997).
  • two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism).
  • Altered drug action may occur in a patient having a polymorphism (e.g., an single nucleotide polymorphism or SNP) in promoter, intronic, or exonic sequences of gene95.
  • a polymorphism e.g., an single nucleotide polymorphism or SNP
  • polymorphisms in the promoter region may be critical in determining the risk of HDL deficiency and CVD.
  • polymorphisms of gene95 may likewise be relevant to the identification and use of agents identified using the assays disclosed herein.
  • agents may have different abilities to affect the genes of a signature gene set.
  • a potential therapeutic agent say, agent A
  • agent B a potential agent, say, agent B
  • modulating the activity of the same or related genes causes said expression to be reduced to half, such as where only half as much mRNA is transcribed or only half as much protein is translated from said mRNA as for agent A
  • agent B is considered to have twice as much therapeutic potential as agent A.
  • the present invention also relates to a process that comprises a method for producing a product, including the generation of test data, comprising identifying an agent according to one of the disclosed processes for identifying such an agent (i.e., the therapeutic agents identified according to the assay procedures disclosed herein) wherein said product is the data collected with respect to said agent as a result of said identification process, or assay, and wherein said data is sufficient to convey the chemical character and/or structure and/or properties of said agent.
  • identifying an agent i.e., the therapeutic agents identified according to the assay procedures disclosed herein
  • said product is the data collected with respect to said agent as a result of said identification process, or assay, and wherein said data is sufficient to convey the chemical character and/or structure and/or properties of said agent.
  • the present invention specifically contemplates a situation whereby a user of an assay of the invention may use the assay to screen for compounds having a desired polypeptide, for example, enzyme, modulating activity, or gene expression modulating activity, and, having identified the compound, then conveys that information (i.e., information as to structure, dosage, etc) to another user who then utilizes the information to reproduce the agent and administer it for therapeutic or research purposes according to the invention.
  • a desired polypeptide for example, enzyme, modulating activity, or gene expression modulating activity
  • the user of the assay may screen a number of test compounds without knowing the structure or identity of the compounds (such as where a number of code numbers are used the first user is simply given samples labeled with said code numbers) and, after performing the screening process, using one or more assay processes of the present invention, then imparts to a second user (user 2), verbally or in writing or some equivalent fashion, sufficient information to identify the compounds having a particular modulating activity (for example, the code number with the corresponding results).
  • This transmission of information from user 1 to user 2 is specifically contemplated by the present invention.
  • the present invention relates to a method for producing test data with respect to the modulating activity of a test compound comprising:
  • test data with respect to the modulating activity of said test compound based on a change in the transcription of the determined polynucleotide or reporter gene or activity of the determined polypeptide wherein said change shows modulating activity.
  • Kindred BC11M of Dutch origin was identified as part of a collaboration between the Department of Medical Genetics at the University of British Columbia and St Paul's Hospital in Vancouver, British Columbia. This kindred was ascertained based on a hypoalphalipoproteinemia phenotype ( ⁇ 5 th percentile) in the absence of other lipid and clinical abnormalities (e.g. obesity and diabetes). A history of coronary artery disease was evident in this kindred at the time of ascertainment. Additional Dutch kindreds NL-003, NL-120, were ascertained as part of the patient referral program to the lipid clinic at the Academic Medical Center in Amsterdam based on abnormal cholesterol levels. A control cohort of normolipidemic individuals (HDL >20 th percentile and ⁇ 80 th percentile) was used to validate the causal nature of the mutation.
  • normolipidemic individuals HDL >20 th percentile and ⁇ 80 th percentile
  • chromosome 9 was supported by multipoint linkage analysis, and the multipoint LOD rose to 8.0, defining an affecteds only interval of 20.91 cM (Interval 1; D9S1780 to 9q22xca17) (Table 2). This interval could be further into sub-regions based on chromosomal breakpoints in unaffected individuals (Interval 2; 9q22xca7 to 9q22x-ca17) (Interval 3; D9S1812 to D9S1803x) (Table 2). Interval 2 was the focus for the most comprehensive mutation detection effort.
  • cDNA clones arrayed into a multi-well PCR plate were obtained from Origene (Rockville, MD). PCR was performed using gene-specific primers for Gene 95 (sometimes "G95" herein). Reactions were in 10 ⁇ l and contained 1.0 ⁇ l 10x buffer (Roche Molecular Biochemicals, Indianapolis, IN, USA), 0.25 mM of each dNTP (Boehringer Mannheim), 5 pmole of forward primer and reverse primer, and 0.25 unit of Taq DNA polymerase (Roche Molecular Biochemicals, Indianapolis, IN, USA).
  • the amplified fragment lies between exons 4 and 6, and has a product size of 230 bp.
  • DNA Engine Tetrad cyclers (MJ Research, Inc., Waltham, MA, USA) were used for PCR amplification.
  • the conditions for PCR were a 3-min denaturation step at 94°C, followed by 35 cycles at 94°C for 30 sec, 50°C for 30 sec, and 72°C for 1 min. A final extension step of 7 min at 72°C was performed and samples were maintained at 10°C.
  • PCR products were analyzed by electrophoresis on 2% agarose gels in 1x TBE. A 100 bp ladder (Gibco-BRL, Rockville, MD, USA) was used as size standard.
  • the human blot was hybridized with a 401 bp probe for
  • Results show that Gene 95 is ubiquitously expressed with highest levels in muscle and heart. These results were confirmed by Northern blot analysis of mouse tissues (data not shown). In one such run, using fibroblasts, approximately 24 hours prior to cholesterol treatment, 2 x 10 5 cells were plated into each well in a 6-well format so as to obtain 50-70% confluency the following day. Cells were treated with a final concentration of 30 ⁇ g/ml cholesterol for 24 h followed by total RNA preparation. The control was Gene 95 expression from unaffected cell lines.
  • Reverse primer 5' CCTTTGTAAAAGCCATCAGGAAACT-3' SEQ ID NO. 32
  • RT-PCR was carried out in an ABI 7900 sequence detection system in a final volume of 25 ul, containing 120 ng of total RNA for human Gene 95 or 50 ng for human apoA1 , 200 ⁇ M primers, and 600 ⁇ M probe in 1x Taqman one-step RT-PCR Master mix (Applied Biosystem, CA).
  • ⁇ CT for the calibrator and samples was obtained by subtracting the VIC C ⁇ value of 18s RNA or GAPDH from the FAM C ⁇ value of the gene of interest.
  • ⁇ C T was calculated by subtracting the average ⁇ CT
  • RNA RNA, and reactions with RNA but without reverse transciptase were used as negative controls.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus For Radiation Diagnosis (AREA)

Abstract

L'invention concerne des compositions et des procédés pour la modulation de niveaux de HDL cholestérol et/ou de traitement d'une maladie vasculaire, d'une dyslipidémie et d'un trouble associé chez un patient en ayant besoin. L'invention porte également sur des méthodes d'identification d'agents thérapeutiques pour le traitements desdits troubles en fonction de l'identification desdites nouvelles cibles thérapeutiques. Elle se rapporte encore à des compositions diagnostiques et pharmacogénomiques et à des méthodes dans lesquelles les cibles de l'invention sont utilisées.
PCT/US2003/020410 2002-06-27 2003-06-27 Nouvelle cible therapeutique pour le traitement de maladies vasculaires, de dyslipidemies et de troubles associes WO2004003159A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2004518026A JP2006504407A (ja) 2002-06-27 2003-06-27 血管障害、異常脂質血症および関連疾患の治療用の新規治療標的
EP03762177A EP1551856A2 (fr) 2002-06-27 2003-06-27 Nouvelle cible therapeutique pour le traitement de maladies vasculaires, de dyslipidemies et de troubles associes
AU2003247810A AU2003247810A1 (en) 2002-06-27 2003-06-27 Novel therapeutic target for treating vascular diseases, dyslipidemias and related disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39187802P 2002-06-27 2002-06-27
US60/391,878 2002-06-27

Publications (2)

Publication Number Publication Date
WO2004003159A2 true WO2004003159A2 (fr) 2004-01-08
WO2004003159A3 WO2004003159A3 (fr) 2004-10-21

Family

ID=30000767

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/020410 WO2004003159A2 (fr) 2002-06-27 2003-06-27 Nouvelle cible therapeutique pour le traitement de maladies vasculaires, de dyslipidemies et de troubles associes

Country Status (4)

Country Link
EP (1) EP1551856A2 (fr)
JP (1) JP2006504407A (fr)
AU (1) AU2003247810A1 (fr)
WO (1) WO2004003159A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7928083B2 (en) 2007-01-16 2011-04-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE NCBI [Online] 25 February 2001 BABBAGE A.: 'Human DNA sequence from clone RP11-244N9 on chromosome 9, complete sequence', XP002981262 Database accession no. (AL162385) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7928083B2 (en) 2007-01-16 2011-04-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis

Also Published As

Publication number Publication date
WO2004003159A3 (fr) 2004-10-21
EP1551856A2 (fr) 2005-07-13
AU2003247810A1 (en) 2004-01-19
AU2003247810A8 (en) 2004-01-19
JP2006504407A (ja) 2006-02-09

Similar Documents

Publication Publication Date Title
AU2010202722B2 (en) Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof
JP4726302B2 (ja) Ａｂｃ１ポリペプチドおよびコレステロール水準を調節する方法と試薬
JP2002501376A (ja) 新規のｌｄｌ−レセプター
JP2004504054A (ja) 薬物誘導型心臓不整脈に関係するｓｃｎ５ａ中の一般的多型
EP1366183A2 (fr) Procede destine au diagnostic et au traitement de troubles mentaux
EP1852505B1 (fr) Mutations dans des canaux d'ion
KR20170041955A (ko) 근위축성측삭경화증에 대한 진단 마커로서의 돌연변이 유전자 및 이를 이용한 진단방법
US20050153287A1 (en) Nr3b nmda receptor subunit compositions and related methods
AU767718B2 (en) Novel mutations in the (FREAC3) gene for diagnosis and prognosis of glaucoma and anterior segment dysgenesis
US20060141462A1 (en) Human type II diabetes gene-slit-3 located on chromosome 5q35
WO2004003159A2 (fr) Nouvelle cible therapeutique pour le traitement de maladies vasculaires, de dyslipidemies et de troubles associes
US20030054446A1 (en) Novel retina-specific human proteins C7orf9, C12orf7, MPP4 and F379
US7462447B2 (en) Methods for evaluating susceptibility to a bone homeostasis disorder
WO2005024024A1 (fr) Mutations dans la famille des genes nedd4 impliquees dans l'epilepsie et autres troubles du snc
US20030129631A1 (en) Gene family with transformation modulating activity
EP1045926B1 (fr) Famille de genes possedant une activite de modulation de la transformation
WO2002080842A2 (fr) Medicament et procede de diagnostic d'un etat auto-immun
WO2002020848A2 (fr) Gene et variation de sequence associes au cancer
US20030079236A1 (en) Polymorphisms associated with internalizing disorders
AU9679998A (en) Methods to modulate blood pressure and diagnose bartter's syndrome type iii
US6395488B1 (en) Cholecystokinin (CCK) gene as a risk factor for smoking in women
US20030224423A1 (en) Method of testing for allergic diseases
Liang United States Patent te
WO2004103316A2 (fr) Nouvelle cible therapeutique orp9 d'augmentation des niveaux de hdl

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004518026

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003762177

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003762177

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003762177

Country of ref document: EP